

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/625,839	07/23/2003	George J. Brewer	30275/40887	9547
	7590 02/21/2008	D .	EXAM	INER
MARSHALL, GERSTEIN & BORUN LLP 233 S. WACKER DRIVE, SUITE 6300			FAY, ZOHREH A	
SEARS TOWER CHICAGO, IL 60606			ART UNIT	PAPER NUMBER
00.,120,120			1612	
			MAIL DATE	DELIVERY MODE
			02/21/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/625,839	BREWER ET AL.			
Office Action Summary	Examiner	Art Unit			
	ZOHREH A. FAY	1612			
The MAILING DATE of this communicati	on appears on the cover sheet w	ith the correspondence address			
Period for Reply	DEDLY 10.057 TO 5YDIDE 0.M	IONTHIO) OR THIRTY (20) RAVE			
A SHORTENED STATUTORY PERIOD FOR WHICHEVER IS LONGER, FROM THE MAIL!  - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communica.  - If NO period for reply is specified above, the maximum statutory.  - Failure to reply within the set or extended period for reply will, be any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF THIS COMMUNICER 1.136(a). In no event, however, may a retion.  y period will apply and will expire SIX (6) MON by statute, cause the application to become AB	CATION. reply be timely filed ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status	·				
1) Responsive to communication(s) filed or	n <u>30 November 2007</u> .				
,	, —				
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice u	nder <i>Ex parte Quayle</i> , 1935 C.D.	). 11, 453 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>1-27</u> is/are pending in the appli	cation.	·			
4a) Of the above claim(s) is/are w	ithdrawn from consideration.				
5) Claim(s) is/are allowed.	,				
6)⊠ Claim(s) <u>1-27</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction	and/or election requirement.	·			
Application Papers					
9) The specification is objected to by the Ex	aminer.				
10) The drawing(s) filed on is/are: a)	accepted or b) objected to	by the Examiner.			
Applicant may not request that any objection	to the drawing(s) be held in abeyar	nce. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the 11) The oath or declaration is objected to by	•				
Priority under 35 U.S.C. § 119	•				
12) Acknowledgment is made of a claim for f a) All b) Some * c) None of:	oreign priority under 35 U.S.C. §	§ 119(a)-(d) or (f).			
1. Certified copies of the priority doc	uments have been received.				
2. Certified copies of the priority doc	uments have been received in A	pplication No			
3. Copies of the certified copies of the	•	received in this National Stage			
application from the International I	, , , , , , , , , , , , , , , , , , , ,				
* See the attached detailed Office action for	r a list of the certified copies not	received.			
Attachment(s)					
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-9)</li> </ol>		Summary (PTO-413) s)/Mail Date			
<ul> <li>2) Motice of Draftsperson's Patent Drawing Review (PTO-93)</li> <li>3) Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	5)  Notice of I	nformal Patent Application			

Application/Control Number: 10/625,839

Art Unit: 1612

Claims 1-27 are presented for examination.

The amendments and remarks filed on November 30, 2007 have been received and entered.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Application/Control Number: 10/625,839

Art Unit: 1612

Claims 1-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO00/13712.

The WO patent teaches the use of tetrathiomolybdate in a pharmaceutical formulation for treating tumor. See page 7, lines 7-10. The addition of Zinc is taught on page 10, line 9. The addition of other chemotherapeutic agents is taught on page 7, lines 12-20. The addition of penicillamine is taught on page 33, lines 20-32. The ammonium salt of thiomolybdate is taught on page 28, lines 6-8. The above reference differs from the claimed invention in the specific ammonium salt of thiomolybdat. It would have been obvious to a person skilled in the art to use any salt of thiomolybdate with ammonium, considering that the relied upon reference teaches the use of the ammonium salt of thiomolybadte in general in a pharmaceutical formulation for the treatment of tumor. One skilled in the art would have been motivated to employ the teachings of the above reference, since it relates to the ammonium salt of thiomolybdate in combination with secondary ingredients, such as zinc and other chemotherapeutic agents for the treatment of tumor.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZOHREH A. FAY whose telephone number is (571)272-0573. The examiner can normally be reached on Monday to Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Fredrick Krass can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Page 4

Application/Control Number: 10/625,839

Art Unit: 1612

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Z.F /Zohreh A Fay/ Primary Examiner, Art Unit 1612